| Nov 21 |
Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
|
| Nov 21 |
Novartis buys gene therapy developer Kate for up to $1.1B
|
| Nov 21 |
Novartis raises mid-term sales guidance
|
| Nov 21 |
Novartis Lifts Midterm Sales Guidance Amid U.S. Expansion
|
| Nov 21 |
Novartis wagers more than $1B on gene therapies for the nervous system
|
| Nov 21 |
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
|
| Nov 19 |
Novartis ranks first in 2024 Access to Medicine Index
|
| Nov 19 |
Novartis strengthens radiopharma leadership with Ratio Therapeutics deal
|
| Nov 19 |
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
|
| Nov 18 |
Novartis, Ratio to collaborate on SSTR2 radiotherapeutic for cancer
|
